Healthcare Strategy Consulting

Updated September 2026 · Written and maintained by the Progression Agency strategy team

Healthcare is not one consulting market. A hospital system, an insurer, a pharmaceutical company and a digital health startup face problems with almost nothing in common, and firms genuinely strong in one segment are frequently weak in the others. On top of that sits the structural difference that makes generalist strategy work misfire here: the person receiving the service is often not the person paying, regulation is the market rather than a constraint on it, and clinical judgment bounds what commercial logic may recommend.

What does healthcare strategy consulting actually cover?

Corporate and growth strategy, market access and pricing, commercial and launch planning, operational improvement, digital and data strategy, and transaction support — across providers, payers, life sciences and health technology.

The category is unusually broad because ‘healthcare’ spans organizations with almost nothing in common. A hospital system, a pharmaceutical company, an insurer and a digital health startup face entirely different problems, and firms strong in one segment are frequently weak in the others.

Corporate and growth strategy

Where an organization should compete, what to build, buy or exit, and how to allocate capital across services or a portfolio.

Market access and pricing

For therapeutics and devices: reimbursement pathways, payer evidence requirements, health economics, and pricing across markets with different systems.

Commercial and launch planning

Segmentation, targeting, field force sizing, channel strategy and the sequencing of a product introduction.

Provider operations

Throughput, capacity, workforce planning, service line performance and cost structure in hospitals and health systems.

Payer strategy

Network design, benefit structure, risk arrangements and the analytics that underpin them.

Digital health and data

Where technology genuinely changes economics rather than adding a layer, and what the data actually supports.

Regulatory and policy analysis

Understanding what reimbursement, coverage and regulatory changes mean commercially, which is a different skill from legal compliance.

Transaction and diligence support

Commercial due diligence for investors and acquirers, which is a distinct practice with its own timelines and standards.

Post-merger integration

Combining clinical services, systems and cultures, where most healthcare transaction value is won or lost.

Quality and clinical improvement

Outcomes, safety and pathway redesign, which requires clinical credibility a purely commercial firm will not have.

Why is healthcare unlike other consulting markets?

Because the person receiving the service is frequently not the person paying, regulation shapes the economics, and decisions have clinical consequences that constrain what commercial logic can recommend.

That third point is the one generalist strategy work handles badly. A recommendation that improves margin and worsens clinical outcomes is not a trade-off to be optimized; in most healthcare settings it is not available at all.

The payer is not the patient

Demand, price sensitivity and switching behavior all work differently when a third party pays. Standard commercial frameworks frequently mislead here.

Regulation is the market structure

Reimbursement rules, coverage decisions and approval pathways are not constraints on the market; in large parts of healthcare they are the market.

Clinical judgment bounds the analysis

Recommendations affecting care delivery need clinical input, and firms without it produce work that clinicians will not implement.

Data is abundant and hard to use

Healthcare generates enormous data and access is constrained by privacy law, fragmentation and interoperability problems that consume project time.

Timelines are long

Product development, evidence generation and system change all run in years. Strategy work has to be robust across a longer horizon than most industries require.

Stakeholders are numerous

Clinicians, administrators, payers, regulators, patients and boards all have standing. Recommendations that ignore any of them tend not to survive implementation.

What kinds of firm operate here?

Global strategy firms with healthcare practices, healthcare-specialist consultancies, life sciences boutiques, provider-focused operational firms, and analytics-led specialists.

The right answer depends almost entirely on which segment you are in and whether the problem is strategic, operational or analytical. A firm excellent at payer analytics is not the firm for a hospital’s service line redesign.

Global strategy firms

Deep resources, board-level credibility and broad benchmarks, at the highest cost. Best where the question is genuinely corporate and the answer needs institutional weight behind it.

Healthcare-specialist consultancies

Sector depth without global overhead. Frequently the strongest option for mid-market providers and life sciences companies, and the segment where quality varies most.

Life sciences boutiques

Narrow expertise in market access, health economics, launch or regulatory strategy. Excellent within scope and not built for broad corporate questions.

Provider operations firms

Hospital and system improvement, frequently with clinical staff and implementation capability. The right choice when the problem is throughput or cost rather than positioning.

Analytics and data specialists

Claims analysis, real-world evidence, outcomes modeling. Increasingly the substance behind other firms’ recommendations.

Independent advisers

Former operators and executives working alone. Senior judgment without delivery capacity, which suits organizations that can execute themselves.

Which firms actually do healthcare strategy consulting?

They fall into three groups: global strategy and professional services firms with healthcare practices, healthcare and life sciences specialists, and analytics-led firms. The firms below all publish a healthcare or life sciences practice.

Listed alphabetically, not ranked. Which of them is right for you depends almost entirely on your segment and on whether the problem is strategic, operational or analytical — a distinction no list can make for you.

• Bain & Company — global strategy firm with a healthcare and life sciences industry practice.
• Boston Consulting Group — global strategy firm working with payers, providers, device and pharmaceutical companies.
• ClearView Healthcare Partners — life sciences strategy specialist.
• Deloitte — health care industry — strategy, operations and technology across the health sector.
• IQVIA — life sciences data, analytics and technology.
• McKinsey & Company — global strategy firm with a healthcare practice.
• Milliman — health — actuarial and data analytics work across healthcare.
• Oliver Wyman — health and life sciences — strategy with strong payer and actuarial depth.
• Putnam, within Inizio — life sciences strategy specialist, now part of the Inizio group.
• West Monroe — healthcare — access, operations and technology consulting for providers and payers.
• ZS — go-to-market, analytics and access strategy for life sciences.

The useful way to read that table is by the middle column rather than the first. A payer with a network design question and a device company with a reimbursement question are looking at different halves of this list, and hiring across the divide is the most common and most expensive selection error in this market.

Global strategy firms

Bain, BCG, Deloitte, McKinsey and Oliver Wyman all maintain healthcare practices. They bring board credibility, cross-market benchmarks and depth of resource, at the highest cost and with the leverage model that implies.

Life sciences specialists

ClearView and Putnam concentrate on pharmaceutical and biotech questions — market access, launch, evidence and pricing. Narrow by design, and stronger inside that scope than a generalist typically is.

Analytics-led firms

IQVIA, Milliman and ZS lead with data. Where the substance of the question is modeling — actuarial work, claims analysis, commercial analytics — this group is frequently doing the work that other firms’ recommendations rest on.

Operational and digital firms

West Monroe and firms like it focus on implementation and operations rather than positioning, which matters when the problem is throughput, access or systems rather than direction.

Who is missing from a list like this

Regional and provider-focused firms, clinical improvement specialists, and independent advisers — frequently the right answer for a single hospital system and almost never visible in a national list, because they do not need to be.

How do you scope a healthcare strategy engagement?

By naming the decision it is meant to inform, who will make it, when, and what evidence would change their mind.

Engagements that begin without a decision attached produce documents rather than outcomes. The most useful question in a scoping conversation is what will be done differently depending on what the work finds.

Name the decision, not the topic

‘Should we open a second ambulatory site’ is a decision; ‘market assessment’ is a topic. The first produces usable work and the second produces a report.

Establish who decides and when

Board timetables, budget cycles and regulatory deadlines determine when analysis is useful. Work delivered after a decision has been taken is expensive documentation.

Agree what evidence would change the answer

If no possible finding would alter the plan, the engagement is validation rather than analysis, and should be priced and scoped as such.

Define the data you can actually provide

Access to internal data is the most common cause of delay. Establish what exists, who owns it, and what approvals are needed before committing to a timeline.

Decide whether implementation is included

Strategy without implementation is where a great deal of healthcare consulting value is lost, and it should be a deliberate choice rather than a discovery.

Set the clinical involvement explicitly

Which clinicians will be consulted, when, and with what authority. Work that surprises clinical leadership at the end does not get implemented.

What does it cost?

Widely variable: from roughly $50,000 for a focused analysis to several million for a large multi-workstream program, with global firms at the top of every band.

Cost tracks team seniority and duration rather than sector difficulty. The most useful comparison is not the total but the day rate and the composition of the team actually assigned.

These are indicative category ranges rather than quotes, and the spread within each is wide. What matters commercially is whether the decision at stake justifies the spend, which is a calculation the buyer can do and frequently does not.

Ask who is actually on the team

Partner time is what you are paying a premium for and frequently what you receive least of. Ask for the named team and the proportion of senior time.

Understand the leverage model

Large firms staff with many juniors and few seniors, which is efficient and means most of your interaction is with people early in their careers.

Fixed fee versus time and materials

Fixed fee transfers scope risk to the firm and creates an incentive to finish; time and materials transfers it to you. Both are legitimate and the choice should be deliberate.

How do you judge a healthcare consulting firm?

By segment-specific experience, clinical credibility where relevant, who is actually assigned, and whether they will tell you something you did not want to hear.

Sector experience matters more here than in most consulting because the regulatory and reimbursement detail is genuinely hard to acquire quickly. A firm learning your segment on your engagement is being paid to be trained.

1. Which specific healthcare segments have you worked in, and on what problems?
2. Who exactly will be on this team, and what is the senior time proportion?
3. Do you have clinical input, and how is it involved?
4. What data do you need from us, and by when?
5. Is implementation included, or does the engagement end at recommendations?
6. What have you recommended that a client rejected, and why?
7. How do you handle a finding that contradicts what we hoped?
8. What would you tell us not to do?

Question six is the most revealing. A firm that has never had a recommendation rejected has either had a very short history or has been telling clients what they wanted, and both are worth knowing before committing.

Segment experience is not sector experience

Healthcare is not one market. Ask specifically about providers, payers, pharmaceutical, device or digital health rather than accepting ‘healthcare experience’ as an answer.

Clinical credibility is checkable

Ask who the clinicians are, what they practice, and how current they are. Clinical input from somebody who left practice fifteen years ago is a different thing from active involvement.

Conflicts are common and worth asking about

Firms advise payers and providers, manufacturers and purchasers. Ask directly what conflicts exist and how they are managed rather than assuming they have been.

Beware benchmark-driven answers

Benchmarks are useful and they describe what other organizations did, not what you should do. A recommendation that is entirely benchmark-derived has not engaged with your situation.

What goes wrong in these engagements?

Recommendations that ignore clinical reality, data access delays, findings arriving after the decision, and strategies with no implementation path.

Almost all of these are scoping failures rather than analytical ones. The analysis is usually competent; what fails is the connection between the analysis and anything actually changing.

Data access is the usual delay

Internal data is fragmented, owned by different functions and subject to privacy approvals. Establishing access before the engagement starts saves weeks that otherwise come out of the analysis.

Clinical buy-in cannot be retrofitted

A recommendation presented to clinicians at the end will be contested at the end. Involving them throughout costs time and is the difference between a strategy and a document.

The board timetable is the real deadline

Work that misses the meeting it was commissioned for loses most of its value regardless of quality.

Implementation capability is separate

Firms good at analysis are frequently not good at delivery, and the transition between the two is where programs stall.

Consultant dependence accumulates

Organizations that outsource thinking repeatedly lose the internal capability to do it, which raises the cost of every subsequent decision.

How should the work be measured?

Against the decision it informed and what changed as a result — not against the deliverable.

A completed report is not an outcome. The measurable questions are whether the decision was taken, whether it was better informed, and whether the recommended changes were actually implemented.

The last two rows are the ones that separate an engagement that helped from one that produced a document, and both are agreeable in advance at no cost.

When should you not hire a strategy firm?

When the decision has already been made, when the problem is execution rather than direction, and when the internal team could do it with time you are unwilling to give them.

The first is common and expensive. Commissioning analysis to justify a decision already taken is a legitimate political activity and should be recognized as such rather than confused with strategy work.

How long do these engagements take?

Four to eight weeks for a focused question, eight to fourteen for a market assessment, three to six for diligence on a transaction timetable, and four to nine months for a full program.

Diligence is the outlier: the timetable is set by the transaction and cannot flex, which changes how the work is staffed and what depth is achievable.

Diligence timelines are immovable

A transaction closes on its own schedule. That is why diligence practices are structured differently and why firms without one struggle to deliver against those deadlines.

Longer is not better

Programs stretching past nine months usually indicate scope that was never properly defined, and the marginal analysis is rarely what changes the decision.

Should you run a competitive process?

For anything substantial, yes — and keep it to three firms and a real brief rather than eight and a vague one.

A well-written brief produces comparable proposals and reveals which firms actually understood the question. A vague brief produces eight decks describing capability, which is the least useful document any of them can write.

Write the brief around the decision

The same discipline that scopes the work also produces proposals you can compare. Firms respond to what they are asked.

Ask for the team, not the firm

Proposals describe institutional capability; engagements are delivered by three or four named people whose experience is what you are actually buying.

What is the relationship between strategy and implementation?

The value is realized in implementation and the fee is usually paid for strategy, which is why so many engagements end with a document and no change.

Deciding at the outset whether the firm stays through delivery, hands over to another party, or hands to your own team — and staffing for that — is the single most consequential scoping decision after naming the decision itself.

What questions should the board ask about the work?

What was rejected and why, where the evidence is weakest, what would have to be true for this to fail, and who will own delivery.

Boards are frequently presented with a recommendation and its supporting case, which is the least informative version of the work. The interesting material is the options that were discarded and the assumptions the conclusion depends on.

Ask what would have to be true

A recommendation depends on assumptions. Naming the two or three that matter most, and how confident anyone is in them, tells a board more than the conclusion does.

Ask who owns it on Monday

A strategy with no named internal owner and no allocated time is a document. This question at the presentation prevents a year of drift.

How do you avoid buying validation by accident?

By writing down, before commissioning, what result would cause you to change course — and circulating it.

If nobody can name such a result, the organization has already decided and the engagement is political cover. That may be a reasonable thing to buy; it is not a reasonable thing to buy unknowingly at strategy-program prices.

How do you keep the capability in-house afterwards?

By putting capability transfer in the scope, having internal people work alongside the team, and insisting the models and their assumptions are handed over in usable form.

The most common outcome of a good engagement is an organization that can no longer do the analysis itself the following year. That is expensive and it is avoidable by making the transfer an explicit deliverable.

The last row is the mark of a good firm. Work that presents every conclusion with equal confidence is hiding the parts where the evidence was thin, and those parts are exactly where a board should be paying attention.

How does this differ for digital health companies?

Shorter horizons, less internal data, funding-cycle timelines, and a buyer who frequently needs commercial validation more than strategic direction.

Early-stage health technology companies frequently need evidence that a market exists and that payers will pay, which is a market access question dressed as a strategy question. Getting that distinction right changes which firm to hire.

What about providers and health systems specifically?

Operational and service line work dominates, clinical involvement is essential, and implementation capability matters more than analytical brilliance.

Hospital strategy that cannot be implemented by the people who run the wards is not strategy. The firms that succeed in this segment generally have clinical staff and stay through delivery.

What about payers and insurers?

Analytics-heavy, regulation-bound, and increasingly focused on network design and risk arrangements where the modeling is the substance of the work.

This is the segment where analytical capability matters most and where a firm without genuine claims data experience will struggle to produce anything a payer’s own team could not.

What about pharmaceutical and device companies?

Market access and launch dominate, evidence requirements drive everything, and the work is frequently global with market-by-market variation.

Pricing and reimbursement differ so substantially between health systems that a strategy which works in one market can be unusable in another, and firms without genuine multi-market experience underestimate this consistently.

The landscape: who does what, and how the firms differ

“Healthcare consulting” spans strategy, operations, policy and technology, and firms that look interchangeable from outside rarely compete for the same work.

Reading a list of healthcare consulting firms

Any list of healthcare consulting firms mixes global strategy practices, specialist boutiques and technology implementers. The useful sort is by what they are hired to decide, not by revenue — a firm that models service-line profitability is not an alternative to one that configures an electronic health record.

Hospital consulting

Hospital consulting firms concentrate on throughput, staffing, service-line performance and capital planning. The work is operational and heavily benchmarked, and the deliverable is usually a change to how a department runs rather than a strategy document.

Healthcare policy consulting

Healthcare policy consulting sits closer to government affairs — reimbursement change, regulatory response, and modeling what a rule change does to a provider’s economics. It draws on different people entirely, frequently ex-regulators rather than ex-operators.

Technology and digital

Healthcare technology consulting firms handle system selection, implementation and interoperability. The distinguishing question is whether they will still be present after go-live, since the difficult phase of an EHR program is the year afterwards.

Boutiques

Small healthcare consulting firms compete on the partner actually doing the work rather than on bench depth. For a single well-defined decision that is frequently the better trade; for a multi-year program needing surge capacity it is not.

Hospital operations, and market access

Healthcare consulting categories that sit outside marketing.

Operations management hospital work covers patient flow, capacity and staffing, theater and clinic scheduling, and the supply chain that supports all of it. It is where most of the improvable cost in a provider sits, and it constrains marketing directly: demand generated for a service line with no available appointments produces a worse patient experience than no demand at all.

Health management companies operate or support the business side of practices and facilities — administration, billing, contracting and compliance — leaving clinical decisions with clinicians. The model is common in dental, veterinary and specialty physician groups, and it is usually what is behind a group of practices sharing a marketing function.

Healthcare market access is the pharmaceutical and device discipline of getting a product covered, reimbursed and available: payer negotiation, health economics evidence, formulary placement and pricing across markets. It is not marketing, and confusing the two is expensive, because a product with excellent awareness and no reimbursement does not sell.

Pharmaceutical web development sits under both, since the sites are subject to promotional regulation, adverse-event reporting obligations on any interactive feature, and a medical, legal and regulatory review step between every draft and publication.

Frequently asked questions